Table 4. Univariate analysis of sustained viral response (SVR) rates observed from the IDEAL pharmacogenomics cohort for IL28B heterozygous patients with high or low low-density lipoprotein cholesterol (LDL-C) (≤/>130 mg/dL) compared with other prognostic factors associated with SVR.

Clinical factor	LDL-C > 130 mg/dL SVR % (n/N)	LDL-C ≤ 130 mg/dL SVR % (n/N)	P-value*
HCV RNA ≤600 000 IU/mL	71% (12/17)	53% (59/112)	0.00014
HCV RNA >600 000 IU/mL	43% 37/87	24% (126/532)
F0–F2 METAVIR fibrosis	47.9% (45/94)	30.6% (175/571)	0.00033
F3–F4 METAVIR fibrosis	40.0% (4/10)	13.7% (10/73)
Non-African American	53.8% (42/78)	30.6% (165/533)	0.00008
African American	26.9% (7/26)	18.0% (10/73)
Normal fasting blood glucose	50.0% (43/86)	31.5% (165/524)	0.00030
Abnormal fasting blood glucose	33.3% (6/18)	16.7% (20/120)

^*Cochran–Mantel–Haenszel test compares SVR rates for high vs low LDL-C after adjusting for hepatitis C virus (HCV) RNA level, METAVIR fibrosis, race, abnormal fasting glucose.